FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
The FDA issued reminders to over 2,200 sponsors and researchers regarding their mandatory obligations to submit clinical trial results information to the ClinicalTrials.gov database.
Medical product companies, academic researchers, and clinical trial sponsors responsible for data submission and regulatory reporting.
The scale of this outreach suggests a broad enforcement focus on data transparency and public disclosure requirements. This mass notification could be a precursor to more formal enforcement actions, such as Pre-Notices of Noncompliance or civil money penalties, for entities that fail to rectify missing or late submissions. Regulatory teams may need to interpret this as a signal that the agency is prioritizing post-market reporting integrity.
Clinical operations and regulatory teams should immediately audit their ClinicalTrials.gov portfolio to ensure all required results for applicable trials have been submitted according to statutory timelines. Verification of data entry accuracy and completion status for historical studies is advised to mitigate potential enforcement.
The U.S. Food and Drug Administration has reminded more than 2,200 medical product companies and researchers of the requirements to submit certain clinical trial results information to ClinicalTrials.gov.
Open in openFDA / FDA.gov